Revlimid 5 mg Capsules Special Use-results Surveillance of Transformation to Acute Myeloid Leukemia
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Jun 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 06 Jun 2017 Planned End Date changed from 1 Mar 2017 to 31 Dec 2019.
- 06 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 31 Dec 2019.
- 05 Oct 2016 New trial record